A detailed history of Trexquant Investment LP transactions in Harrow Health, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 4,956 shares of HROW stock, worth $181,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,956
Previous 12,758 61.15%
Holding current value
$181,587
Previous $266,000 16.54%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$20.85 - $46.47 $162,671 - $362,558
-7,802 Reduced 61.15%
4,956 $222,000
Q2 2024

Aug 13, 2024

BUY
$10.0 - $21.64 $127,580 - $276,083
12,758 New
12,758 $266,000
Q3 2023

Nov 13, 2023

BUY
$14.03 - $22.08 $617,123 - $971,210
43,986 New
43,986 $632,000
Q4 2022

Feb 13, 2023

SELL
$10.28 - $14.78 $246,236 - $354,025
-23,953 Reduced 40.6%
35,039 $517,000
Q3 2022

Nov 14, 2022

BUY
$6.57 - $24.88 $194,859 - $737,915
29,659 Added 101.11%
58,992 $712,000
Q2 2022

Aug 11, 2022

BUY
$5.75 - $7.74 $93,799 - $126,262
16,313 Added 125.29%
29,333 $214,000
Q1 2022

May 13, 2022

BUY
$6.77 - $8.66 $12,104 - $15,484
1,788 Added 15.92%
13,020 $89,000
Q4 2021

Feb 14, 2022

BUY
$8.5 - $12.0 $95,472 - $134,784
11,232 New
11,232 $97,000
Q2 2021

Aug 12, 2021

SELL
$6.68 - $11.07 $163,960 - $271,713
-24,545 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$6.26 - $11.03 $73,648 - $129,767
-11,765 Reduced 32.4%
24,545 $166,000
Q4 2020

Feb 11, 2021

BUY
$4.76 - $6.93 $95,038 - $138,364
19,966 Added 122.16%
36,310 $249,000
Q3 2020

Nov 06, 2020

BUY
$4.71 - $7.36 $76,980 - $120,291
16,344 New
16,344 $91,000
Q2 2019

Aug 09, 2019

SELL
$4.2 - $8.7 $64,814 - $134,258
-15,432 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$4.75 - $7.1 $73,302 - $109,567
15,432 New
15,432 $77,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $992M
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.